ImmunityBio (IBRX) Non Operating Income (2014 - 2026)
ImmunityBio (IBRX) posted quarterly Non Operating Income of -$563.0 million for Q1 2026, down 759.92% year-over-year from $85.3 million in Q1 2025, and down 21837.34% quarter-over-quarter from $2.6 million in Q4 2025.
Powered by 
Analysis
ImmunityBio (IBRX) Non Operating Income (2014 - 2026) Analysis & Trends
ImmunityBio (IBRX) has reported Non Operating Income for 13 consecutive years, with -$563.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Income fell 759.92% year-over-year to -$563.0 million; the TTM figure through Mar 2026 stood at -$593.1 million (down 517.82% YoY), while the FY2025 annual figure was -$95.6 million, down 37.6% from the prior year.
- Non Operating Income eased to -$563.0 million in Q1 2026 per IBRX's latest filing, from $2.6 million in the prior quarter.
- Across five years, Non Operating Income topped out at $10.2 million in Q4 2024 and bottomed at -$563.0 million in Q1 2026.
- Historically, Non Operating Income has averaged -$59.7 million across 5 years, with a median of -$20.4 million in 2022.
- Annual changes were most pronounced in 2024 — Non Operating Income soared 106.9% — and 2026, when it slumped 759.92%.
- ImmunityBio's Non Operating Income stood at -$23.4 million in 2022, then slumped by 532.97% to -$148.1 million in 2023, then soared by 106.9% to $10.2 million in 2024, then sank by 74.66% to $2.6 million in 2025, then sank by 21837.34% to -$563.0 million in 2026.
- Business Quant data shows IBRX's Non Operating Income at -$563.0 million in Q1 2026, $2.6 million in Q4 2025, and -$11.7 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -139.24 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | -53.64 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | -51.63 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | - |
| 10 | ImmunityBio | 8.47 Bn | 8.12 Bn | 50.94 Mn | -168.69 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -168.69 Mn |
| Mar 31, 2026 | -563.00 Mn |
| Dec 31, 2025 | 2.59 Mn |
| Sep 30, 2025 | -11.68 Mn |
| Jun 30, 2025 | -21.02 Mn |
| Mar 31, 2025 | -65.47 Mn |
| Dec 31, 2024 | 10.22 Mn |
| Sep 30, 2024 | -5.50 Mn |
| Jun 30, 2024 | -35.25 Mn |
| Mar 31, 2024 | -38.93 Mn |
| Dec 31, 2023 | -148.07 Mn |
| Sep 30, 2023 | -15.51 Mn |
| Jun 30, 2023 | -53.07 Mn |
| Mar 31, 2023 | -5.00 Mn |
| Dec 31, 2022 | -23.39 Mn |
| Sep 30, 2022 | -20.36 Mn |
| Jun 30, 2022 | -15.21 Mn |
| Mar 31, 2022 | -7.03 Mn |
| Dec 31, 2021 | -12.28 Mn |
| Sep 30, 2021 | -9.59 Mn |